F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib

Citation:
Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G. "F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib." Leukemia research. 2011;35(7):e118-e120. copy at www.tinyurl.com/c2kb8m6

Abstract:

n/a

Notes:

doi: 10.1016/j.leukres.2011.03.021

Website